Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gepirone ER - Fabre-Kramer Pharmaceuticals

Drug Profile

Gepirone ER - Fabre-Kramer Pharmaceuticals

Alternative Names: BMY 13805; EXXUA; MJ 13805; Org 33062; TGFK07AD; Travivo; Variza™

Latest Information Update: 15 Jun 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Fabre-Kramer Pharmaceuticals
  • Class Antidepressants; Anxiolytics; Hypnosedatives; Pyrimidines; Small molecules
  • Mechanism of Action Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Major depressive disorder
  • Phase II Decreased libido; Generalised anxiety disorder

Most Recent Events

  • 15 Jun 2021 Phase-II clinical trials in Decreased libido in USA (PO), prior to June 2021 (Fabre-Kramer Pharmaceuticals pipeline, June 2021)
  • 15 Jun 2021 Phase-II clinical trials in Generalised anxiety disorder in USA (PO), prior to June 2021 (Fabre-Kramer Pharmaceuticals pipeline, June 2021)
  • 15 Jun 2021 Efficacy and adverse events data from multiple clinical trials in Generalised anxiety disorder and Decreased libido released by Fabre-Kramer Pharmaceuticals, prior to June 2021 (Fabre-Kramer Pharmaceuticals website, June 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top